54 16

Please type a plus sign (+) inside this box →

Sheet

Under the Paperwork Reduction Act of 1995, no persons are req Substitute for form 1449A/PTO

6	P	E	
mti	4	non a	>

RECEIVED

Approved for use through 10/31/99. OMB 0651-0031
TECH CENTER 1500/2900 DEPARTMENT OF COMMERCE contains a valid OMB control number

DH I O DO-	5.	, m 4,			1000	14
to respond to a collection	of information	unless it contains a	a valid OMB	control	number	
to respond to a company						_

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known		
09/445,865	/ <u>-</u> G	
	7-28	
February 11, 2000		
Philip John Burke		
1643		
ERD 100]	
	09/445,865 February 11, 2000 Philip John Burke 1643	

			U.S. PATENT DOCU	MENIS		
xaminer Initials*	Cite No.1	US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Passages or Re	Lines, Where Relevant llevant Figures Appear
İ		Number Kind Code ² (if known)	-		CIASS	5060/955
(SW			Rutter, et al.	04-03-1984	435	172
		4,530,901	Weissmann	07-23-1985	435	70
-1:1		4,582,800	Crowl	04-15-1986	¥35	70
-		4,677,063	Mark, et al.	06-30-1987	435	68
		4,678,751	Goeddel	07-07-1987	435	243
=		4,704,362	Itakura, et al.	11-03-1987	435	253
- -		4,710,463	Murray	12-01-1987	435	68
		4,757,006	Toole. Jr., et al.	07-12-1988	435	70
		4,766,075	Goeddel, et al.	08-23-1988	435	240.2
		4,810,648	Stalker	03-07-1989	435	190 191
		 				
		 				
	↓					
		 				
	 	+				
						
					 	

Examine Signature	Communica	Date Considered	
	- Justin	ARER 600 Draw line through citation if not in conformance and not conside	ere

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

RECEIVED

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PARTMENT OF COMMERCE

PARTMENT OF COMMERCE

, te type a plus sign (+) inside this box →	+	
		_

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collect Substitute for form 1449A/PTO	Complete if Known	
INFORMATION DISCLOSURE OF ESTATEMENT BY APPLICANT	Application Number	09/445,865
(use as many sheets as necessary)	Filing Date	February 11, 2000
JUL 1 6 mar &	First Named Inventor	Philip John Burke
(2)	Group Art Unit	1643
heet of 9	Examiner Name	
heet of 9	Attorney Docket Number	ERD 100

					OREIGN PATENT DOCUMEN		Pages, Columns, Lines, Where	Īī
xaminer Initials*	Cite No. ¹	Cite Foreign Patent Document No. 1		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Relevant Passages or Relevant Figures Appear	'	
		Office.3	Number ⁴	Kind Code ⁵ (if known)				L
GN		EP	0 251 744	A2	Delta Biotechnology Ltd.	01-07-1988		1_
<u> </u>	-	EP	0 258 067	A2	Delta Biotechnology Ltd.	03-02-1988		┞-
		EP	0 302 473	A2	Bristol-Myers Co.	02-08-1989		\vdash
		EP	0 415 731	A2	The Wellcome Foundation Ltd.	03-06-1991		_
		wo.	88/07378	A1	Cancer Research Campaign Technology Ltd.	10-06-1988	`	
_		wo	89/10140	A1	Cancer Research Campaign Technology Ltd.	11-02-1989		
-	╁─┈	wo	90/01063	A1	Delta Biotechnology Ltd.	02-08-1990		1_
		wo	91/09867	A1	Imperial Cancer Research Technology Ltd.	07-11-1991		L
		wo	91/11201	A1	Imperial Cancer Research Technology Ltd.	08-07-1991		
W		wo	93/08288	A1	Cancer Research Campaign Technology Ltd.	04-29-1993		ļ
(N	+	wo	93/13805	A1	Bagshawe	07-22-1993		\bot
GN)	+	wo	93/13806	A1	Bagshawe	07-22-1993		\bot
W		wo	95/12678	A1	Cancer Research Campaign Technology Ltd.	05-11-1995		1
w	1	wo	97/07097	A1	Auckland Division Cancer Society of New Zealand	02-27-1997		
on	+	wo	97/24143	Α1	AEPACT, Ltd.	07-10-1997		+
GN	 	wo	97/20580	Α1	AEPACT, Ltd.	06-12-1997		+
GN	+-	wo	97/24143	A1	AEPACT, Ltd.	07-10-1997		+
GN	+	wo	98/22577	A1	Masucci	05-28-1998		4
GW		wo	98/24478	A2	AEPACT, Ltd.	06-11-1998	<u> </u>	丄

ON I	, 30,211.0		
		Date Considered	
Examine	1 ALAN L.	11/24/07	
Signature /	sanswirled _	1// 60/02	
	4		to the state of the second and analysis

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.



L 2 0 2001

Please type a plus sign (+) inside this box →

		٦.
•	1 *	
		1

TECH CENTER AS COMPOSITION OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known 09/445,865 **Application Number** INFORMATION DISCLOSURE ATEMENT BY APPLICANT as many sheets as necessary) February 11, 2000 Filing Date Philip John Burke First Named Inventor 1643 **Group Art Unit** Examiner Name **ERD 100** Attorney Docket Number 9

81	RADE						
		OTHER ART - NON PATENT LITERATURE DOCUMENTS					
Examiner's Cite Initials* No.1		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),					
(W)		ANLEZARK, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)I. Purification and properties of a nitroreductase enzyme from Escherichia colia potential enzyme for antibody-directed enzyme prodrug therapy					
		BETTER, et al., "Escherichia coli secretion of an active chimeric antibody fragment," Science 240(4855):1041-43 (1988).					
		BIRD, et al., "Single-chain antigen-binding proteins," Science 242(4877):423-26 (1988).					
		BISCHOFF, et al., "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells," Science 274(5286):373-76 (1996).					
		BOLAND, et al., "The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)," <i>Biochem. Pharmacol.</i> 41(6-7):867-75 (1991).					
_		BRADL, et al., "Malignant melanoma in transgenic mice," Proc. Natl. Acad. Sci. U. S. A. 88(1):164-68 (1991).					
		BRAWER, "Prostate specific antigen. A review," Acta. Oncol. 30(2):161-68 (1991).					
		CHEN, et al., "Expression of rat liver NAD(P)H:quinone-acceptor oxidoreductase in Escherichia coli and mutagenesis in vitro at Arg-177," <i>Biochem. J.</i> 284 (Pt 3):855-60 (1992).					
		CHEN, et al., "Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse," J. Biol. Chem. 272(3):1437-39 (1997).					
+		CLARK, et al., "Role of the Bp35 cell surface polypeptide in human B-cell activation," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 82(6):1766-70 (1985).					


	A	Data Canaidarad	
Examiner's		Date Considered	
	(a a NS) (a 1000	1//20/02	
Signature	1210011000		
		• •	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.





Please type a plus sign (+) inside this box → +

TECH CENTER 1600/2900 ISBN 88 NO 8A (10-96 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO	1	mplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/445,865
(use a many sheets as necessary)	Filing Date	February 11, 2000
hme.	First Named Inventor	Philip John Burke
JUL 1 6 2001	Group Art Unit	1643
\ <u>e</u>	Examiner Name	
Sheet 4 of 9	Attorney Docket Number	ERD 100
TRADE		ENTS
OTHER ART -	NON PATENT LITERATURE DOCUM (in CAPITAL LETTERS), title of the article ((when appropriate) title of the
Examiner's Cite Include name of the author	(in CAPITAL LETTERS), title of the article (and(s) volume issue number(s)

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
xaminer's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), but and/or country where published	T
(w		CONNORS & WISSON, "Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity," <i>Nature</i> 210(38):866-67 (1966).	
		CORVALAN & SMITH, "Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," <i>Cancer Immunol. Immunother.</i> 24(2):127-32 (1987).	
		CORVALAN, et al., "Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody," Cancer Immunol. Immunother. 24(2):138-43 (1987).	
		CORVALAN, et al., "Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids," Cancer Immunol. Immunother. 24(2):133-37 (1987).	
 		COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc. Natl. Acad. Sci. U. S.</i>	
+		A. 89(13):6094-98 (1992). COUSSENS, et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene," Science 230(4730):1132-39 (1985).	
		CULVER, et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors," Science 256(5063):1550-52 (1992).	
		CURIEL, "Adenovirus facilitation of molecular conjugate-mediated gene transfer," Prog. Med. Virol. 40:1-18 (1993).	
(W)		DRABEK, et al., "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954," Gene Ther. 4(2):93-100 (1997).	L
(M)	<u> </u>	FRIEDLOS & KNOX, "Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system," <i>Biochem. Pharmacol.</i> 44(4):631-35 (1992).	

_			
		Date Considered	
Examiner's	(A) (A)	1,120/02	
Signature	Jankun		
	-7/1	and the second s	an and not considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

RECEIVED

JUL 2 0 2001

Please type a plus sign (+) inside this box →

TECH CENTER 1600/2900 PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known 09/445,865 Application Number INFORMATION DISCLOSURE TATEMENT BY APPLICANT many sheets as necessary) February 11, 2000 Filing Date Philip John Burke First Named Inventor 1643 **Group Art Unit** Examiner Name Attorney Docket Number **ERD 100** 9

	TRA	DE NON DATEST LITERATURE DOCUMENTS
		OTHER ART - NON PATENT LITERATURE DOCUMENTS
xaminer's Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), outlieber city and/or country where published
Cw		FRIEDLOS, et al., "Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)," Biochem. Pharmacol. 44(1):25-31 (1992).
		FRIEDLOS, et al., "Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity," <i>Biochem. Pharmacol.</i> 44(9):1739-43 (1992).
		GILLILAND, et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," Proc. Natl. Acad. Sci. U. S. A. 85(20):7719-23 (1988).
		GREEN, et al., "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene," Cancer Gene Ther. 4(4):229-38 (1997).
		HARWOOD, et al., "Comparative tumour localization of antibody fragments and intact igG in hude mice bearing a CEA-producing human colon tumour xenograft," Eur. J. Cancer Clin. Oncol. 21(12):1515-22 (1985).
		HELLSTRÖM, et al., "Monoclonal mouse antibodies raised against human lung carcinoma;" Cancer Res. 46(8):3917-23 (1986).
		HURRELL, "Monoclonal Hybridoma Antibodies: Techniques and Applications," (CRC Press).
		HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 85(16):5879-83 (1988).
		JACKSON, et al., "The tyrosinase-related protein-1 gene has a structure and promoter sequence very different from tyrosinase," <i>Nucleic Acids Res.</i> 19(14):3799-804 (1991
		JAISWAL, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression," <i>J. Biol. Chem.</i> 269(20):14502-08 (1994).

Examiner's Signature	(IN)	Roll	Date Considered U/20/02
	A	*	Draw line through citation if not in conformance and not considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96

TECH AF NEED of AGO/100749. OMB 0651-0031

Patent and traderial office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	Со	mplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/445,865
(use as many shiets as necessary)	Filing Date	February 11, 2000
JUL 1 6 2001 📈	First Named Inventor	Philip John Burke
	Group Art Unit	1643
	Examiner Name	
	Attorney Docket Number	ERD 100

neet	-		
	-	TO THE THE POOL INTENTS	
		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
aminers	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
nitials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	1
		publisher, city and/or country where published	
00		JAISWAL, "Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second	i
/~//l		member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NAD2 gene leads on	- 1
(M		1. 0 # 0: - 1 20/7\(1990-906 /3990\)	
-	├	KHAN & ROSS, "Tumour-growth inhibitory nitrotheoples and related compounds: structure-activity	- 1
4	ŀ	relationships," Chem. Biol. Interact. 1(1):27-47 (1969).	
		KNOX, et al., "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)II. A comparison of an Escheric	chia
1		KNOX, et al., "The bloactivation of 5-(azirtain 1-y-2)-4 unit of the bloactivation of 5-(azirtain 1-y-2)-4 unit of the bloactivation of 5-(azirtain 1-y-2)-2, unit of 5-(azirtain 1-	1
	l	coli nitroreductase and Walker DT diapnorase, biochem. Thambeon, 44(12),2207 de 14(12)	
- 1 -	İ	and the state of t	<i>,</i>
		KNOX, et al., "The bioactivation of CB 1954 and its use as a product in antibody-directed dizyme products use as a product in antibody-directed dizyme products."	·
l	1	(ADEPT)," Cancer Metastasis Rev. 12(2):195-212 (1993).	1
- 1	1		
		KNOX, et al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated	- 1
	1	prodrugs in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995).	1
1	l		
-	+-	KLIBIYAMA et al. "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a	'
	1	restroyiral vector," Cell Struct, Funct, 16(6):503-10 (1991).	- 1
1	ļ	t al., "The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy "Cancer Metastasis Rev. 12(2):195-212 (1993). t al., "Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated in antibody directed enzyme prodrug therapy (ADEPT)," Biochem. Pharmacol. 49(11):1641-47 (1995). WA, et al., "A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a livector," Cell Struct. Funct. 16(6):503-10 (1991). "Nonviral gene therapy: the promise of genes as pharmaceutical products," Hum. Gene Ther. 6(9):1129-44	
	 	LEDISY, "Neguisal goes therapy: the promise of genes as pharmaceutical products," Hum. Gene Ther. 6(9):1129-	44
ĺ	1		- 1
		(1995).	
	- 	LIAO & WILLIAMS-ASHMAN, "Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamic	le,"
		CIAO & WILLIAMS-ASHMAN, Enzymatic Oxidation of Solid For Programme Conduction of Solid For Programme Conduct	- 1
		Biochem. and Biophys. Res. Comm. 4:208-13 (1961).	- 1
	1	a suidation of some dibudropyridines by polycyclic aromati	c
		LIAO & WILLIAMS-ASHMAN, "Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic	
		hydrocarbons," Biochem. Pharmacol. 6:53-54 (1961).	
			"
_	+	LIAO, et al., "Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide	′ ′′
l l	1	Biol. Chem. 237:2981-87 (1962).	- 1
v	1		

L	 			
Examiner's	1 Rolin	Da	Date Considered	
Signature	 Jan 10 se		11010	4idosod
	¥		o Draw line through citation if not in conformance an	a not considered.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

RECEIVED

JUL 2 0 2001

Please type a plus sign (+) inside this box \rightarrow

TECH CENTER 1600/2008/08A (10.96 d Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known 09/445,865 Application Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT necessary) February 11, 2000 Filing Date Philip John Burke First Named Inventor 1643 **Group Art Unit** Examiner Name **ERD 100** Attorney Docket Number 9 Sheet

eet	
	PRADE TO THE POST OF THE POST
	OTHER ART NON PATENT LITERATURE DOCUMENTS
miner's	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
itials*	the state of the s
litidiə	
	LUNDWALL, "Characterization of the gene for prostate-specific antigen, a human glandular kallikrein," Biochem.
10	Biophys. Res. Commun. 161(3):1151-9 (1989).
/N/	
<u> </u>	MARTIN & PAPAHAJOPOULOS, et al., "Irreversible coupling of immunoglobulin fragments to preformed vesicles. An
1	MARTIN & PAPAHAJOPOULOS, et al., interview 257(1):286-8 (1982).
ì	improved method for liposome targeting," J. Biol. Chem. 257(1):286-8 (1982).
}	MAUGER, et al., "Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction
	MAUGER, et al., "Self-immolative prodrugs: candidates for artibuly directed 612yille prodrug the prodrug the prodrug the product of the produ
- 1	with a nitroreductase enzyme," J. Med. Chem. 37(21):3452-58 (1994).
j	
-+-	MICHAEL, et al., "Addition of a short peptide ligand to the adenovirus fiber protein," Gene Ther. 2(9):660-68 (1995).
	individual strain and
1	
	MILLER & VILE, "Targeted vectors for gene therapy," FASEB J. 9(2):190-99 (1995).
	MILLER & VILE, Talgeted Vectors for gone and the
1	
	MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region
	MORRISON, et al., "Chimeric numari artibody indications in the second of
	domains," Proc. Natl. Acad. Sci. U. S. A. 81(21):6851-55 (1984).
1	NASSANDER, et al., "In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in
	NASSANDER, et al., "In vivo targeting of OV-12 3 immunoliposomes to ascitto ovariant solutions."
	athymic nude mice," Cancer Res. 52(3):646-53 (1992).
1	
	NEUBERGER, et al., "Recombinant antibodies possessing novel effector functions," Nature 312(5995):604-08
	(1984).
	1 1
	O'SULLIVAN, et al., "Comparison of two methods of preparing enzyme-antibody conjugates: application of these
1	conjugates for enzyme immunoassay," Anal. Biochem. 100(1):100-08 (1979).
1	
	RIEGMAN, et al., "Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene,"
1	RIEGMAN, et al., "Characterization of the product opening and all products of the product opening and all products of the products of the product opening and all products of the product opening and all products of the products of the product opening and all products of the product opening and all products of the products of the product of the products of the product of the produ
J/	Biochem. Biophys. Res. Commun. 159(1):95-102 (1989).
•	

1 1		
L		
(-		Date Considered
Examiners	$\sqrt{2}$	11170102
Signature	10000	
		See the station if not in conformance and not considered.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.



JUL 2 0 2001

Please type a plus sign (+) inside this box →

TECH CENTER 1600/2900/s8/08a (10-96
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	collection of information unless it contains a valid OMB control number Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/445,865
(use as many sheets as Recessary)	Filing Date	February 11, 2000
Mr 1 6 mg. 8	First Named Inventor	Philip John Burke
JUL 1 6 2001 E	Group Art Unit	1643
Mark Services	Examiner Name	
A TRADEMA	Attorney Docket Number	ERD 100

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	T.
xaminer's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), etc.), date, page(s), etc.), etc., etc.), etc.,	, i
(W)		SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase," Science 239(4839):487-91 (1988).	
		SAMBROOK, et al., <u>Molecular Cloning: A Laboratory Manual</u> Cold Spring Harbor Laboratory Press, Cold Spring Harbor:New York (1989).	
+		SCHREWE, et al., "Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression," Mol. Cell. Biol. 10(6):2738-48 (1990).	
_		SHARMA, et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model," <i>Br. J. Cancer.</i> 61(5):659-62 (1990).	
		SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy," Adv. Drug Del. Rev. 22:269-88 (1996).	
		SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli," <i>Science</i> 240(4855):1038-41 (1988).	
		TROWELL, "The cytocidal action of mitotic poisons on lymphocytes in vitro," Biochemical Pharmacology 5:53-63 (1960).	
		WAGNER, et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 87(9):3410-14 (1990).	
		WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," <i>Nature</i> 341(6242):544-46 (1989).	
		WHISSON & CONNORS, "Cure of mice bearing advanced plasma cell tumours with aniline mustard," <i>Nature</i> 206(985):689-91 (1965).	

Francisco I		Date Considered	
Examiner's Signature	and the same	1//20/02	
Signature	 	——— <i>••</i> /•/	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96

lease type a plus sign (+) inside this box →	+	

Under the Pape	erwork Reducti	on Act of 1995, no persons are required to respond	to a collection of information unless it contains a va	lid OMB control number	
INFORMATION DISCLOSURE STATEMEN PLY APPLICANT (use as many sheets as successary)		or form 1449A/PTO	Complete if Known		
		EMEN PRY APPLICANT	Application Number	1.1.1	EIVE
	``]	. mnr a	Filing Date	February 11, 2000	-
		TIT 1 p mg. E.	First Named Inventor	Philip John Burke	<u> </u>
	,	\z	Group Art Unit	1643	
		The set	Examiner Name		
Sheet	9	TRADEM 9	Attorney Docket Number	ERD 100	
			NON PATENT LITERATURE DOCUM		
Examiner's Initials*	Cite No. ¹	Include name of the authoritem (book, magazine, journ	or (in CAPITAL LETTERS), title of the article al, serial, symposium, catalog, etc.), date, pa publisher, city and/or country where publish	age(s), volume-issue number(s),	T ²
6			odies," Nature 349(6307):293-99 (
I ~ .	1 1/4/11	at al. "Catabutic proporties of NAT	NPIH:guinone ovidoreductase.7 (NC)	O2) a dibydronicotinamide riboside	1

Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
6		WINTER & MILSTEIN, "Man-made antibodies," <i>Nature</i> 349(6307):293-99 (1991).	
62 62 62		WU, et al., "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase," <i>Arch. Biochem. Biophys.</i> 347(2):221-28 (1997).	
a		ZOLA, "Monoclonal Antibodies: A manual of techniques," (CRC Press, 1988).	
	1		

	 _			
Examiner's Signature	more	W	Date Considered ///20102	
				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.